Topic

Jonathan Sharp is the Chief Financial Officer of 

 He is responsible for the firm's asset management, financial analysis, and case assessment. Since 1990, Environmental Litigation Group, P.C. has advocated for victims of harmful exposure to hazardous chemicals in the workplace.

Articles

Having proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer. 

mRNA Technology: First COVID-19, Now Cancer

VP of Clinical Evidence and Epidemiology, IQVIA

Leveraging RWD can lessen the strain normally put on investigators and sites. 

Using Real-World Data to Examine Long-Term Safety and Effectiveness in Extension Studies

Senior Vice President, Real-World Evidence & Access, Parexel

Vice President of Real-World Evidence Strategy, Parexel

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.

Industry Game Changer: RWE Impacts on Drug Development  

aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.

A New Level of Immunology: Sanjay Shukla, aTyr Pharma

Otsuka Pharmaceuticals Development and Commercialization

MIDD can pave new road for drug development.

Is Model Informed Drug Development Regulatory Pathway an Exception or the Norm?

Dr. Mark Davies is an NHS Consultant and Director of 

. He has a background in marketing and advertising with an MBA and now works extensively with pharma teams supporting market access, brand strategy, commercial performance, partnership projects and real-world data projects (in partnership with Manchester University).

, a consultancy that provides medical affairs advice, resources, and capabilities. Paul has an MBA, a PhD, and is a Chartered Manager. He has 20 years of pharma industry experience, working in medical affairs, clinical development, and commercial roles.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.





Optimizing the Value of Real-World Evidence Projects

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

Q&A: Mark Enyedy, ImmunoGen

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

Advancing in Asthma

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.










Broadening the Scope of Small Molecules: Ventus Therapeutics

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.

R&D/Clinical Trials